Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant vismodegib for large and/or recurrent resectable basal cell carcinoma (phase II)
2016-002856-26Phase 2Completed
- Sponsor
- SRH Wald-Klinikum Gera GmbH
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in basal cell carcinoma (BCC), sponsored by SRH Wald-Klinikum Gera GmbH. Primary endpoint: Primary disease control rate at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2016-002856-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002856-26.